CytomX Therapeutics

CytomX presented positive efficacy data for Varseta‑M in metastatic colorectal cancer at a health conference (ORR 20–30% vs. 1–2% with standard therapy) and emphasized safety‑management improvements, with grade‑3 diarrhea in optimization cohorts falling to about 10%. The company received a $37 million upfront payment from Regeneron, plans a comprehensive data update by the end of 2024, and intends to discuss regulatory strategy with the FDA in 2024. A first registration‑relevant study could start in the first half of 2025; the second lead program, CX‑801, is also expected to deliver initial data in H1 2025. » More on de.investing.com

CytomX presented its Probody portfolio at the Wells‑Fargo conference with Varseta‑M as the only known EpCAM‑targeting ADC in development, showing encouraging phase‑1 data in metastatic colorectal cancer and an FDA fast‑track designation. The company has more than $350 million in liquid assets, supported by an expanded collaboration with Regeneron. The second program, CX‑801 (masked interferon alfa‑2b), has shown initial biomarker activity in melanomas. Key milestones include additional phase‑1 data by the end of 2024, combination data with bevacizumab in H1 2025, and the planned start of a registrational study for Varseta‑M in H1 2027. » More on de.investing.com

CytomX reported an expanded collaboration with Regeneron and received an upfront payment of $37 million for the selection of target molecules for two additional programs; the stock rose about 4.3% in premarket trading. The partnership combines CytomX's PROBODY platform with Regeneron’s Veloci-Bi platform to develop conditionally activated bispecific antibodies against cancer. Regeneron secured the option for up to six additional target molecules; potential total payouts including milestones and commercial payments could amount to around $4 billion, and tiered worldwide royalties are also provided for. » More on de.investing.com